Autophagy positively regulates the CD44+CD24-/low breast cancer stem-like phenotype

Cell Cycle

Volumn 10, Issue 22, 2011, Pages 3871-3885

  Cufí, Sílvia ^a,b   Vazquez Martin, Alejandro ^a,b   Oliveras Ferraros, Cristina ^a,b   Martin Castillo, Begonã ^a   Vellon, Luciano ^c   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c Fundacion Inbiomed   (Spain)

Author keywords

Autophagy; Cancer stem cells; Chloroquine; Claudin low; EMT

Indexed keywords

CD24 ANTIGEN; CD44V ANTIGEN; CHLOROQUINE; MEMBRANE ANTIGEN; PROTEIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER STEM CELL; CONTROLLED STUDY; GENE SILENCING; GENETIC CODE; HUMAN; HUMAN CELL; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

EID: 80655140436     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.22.17976     Document Type: Article

References (112)

1. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119:1438-49; PMID:19487820; DOI:10.1172/JCI38019.
2. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:235-52; PMID:20521089; DOI:10.1007/s10911-010-9175-z.
3. Creighton CJ, Chang JC, Rosen JM. Epithelialmesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:253-60; PMID:20354771; DOI:10.1007/s10911-010-9173-1.
4. de Herreros AG, Peiró S, Nassour M, Savagner P. Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 2010; 15:135-47; PMID:20455012; DOI:10.1007/s10911-010-9179-8.
5. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15:1010-2; PMID:19734877; DOI:10.1038/nm0909-1010.
6. Hollier BG, Evans K, Mani SA. The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009; 14:29-43; PMID:19242781; DOI:10.1007/s10911-009-9110-3.
7. Ouyang G, Wang Z, Fang X, Liu J, Yang CJ. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci 2010; 67:2605-18; PMID:20238234; DOI:10.1007/s00018- 010-0338-2.
8. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29:4741-51; PMID:20531305; DOI:10.1038/onc.2010.215.
9. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; DOI:10.1016/j.cell.2009.11.007.
10. Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59; PMID:19682730; DOI:10.1016/j.cell.2009.06.034.
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; DOI:10.1016/j.cell.2008.03.027.
12. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008; 3:2888; PMID:18682804; DOI:10.1371/journal.pone. 0002888.
13. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11:259-73; PMID:17349583; DOI:10.1016/j.ccr.2007.01.013.
14. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:68; PMID:20813035; DOI:10.1186/bcr2635.
15. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5:5-23; PMID:21147047; DOI:10.1016/j.molonc.2010.11.003.
16. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106:13820-5; PMID:19666588; DOI:10.1073/pnas.0905718106.
17. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69:4116-24; PMID:19435916; DOI:10.1158/0008-5472.CAN-08-3441.
18. Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, et al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS ONE 2010; 5:10240; PMID:20421921; DOI:10.1371/journal.pone. 0010240.
19. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer 2011; 11:68-75; PMID:21150936; DOI:10.1038/nrc2950.
20. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102:789-95; PMID:20104230; DOI:10.1038/sj.bjc.6605551.
21. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8:528-39; PMID:21587219; DOI:10.1038/nrclinonc.2011.71.
22. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8:931-7; PMID:17712358; DOI:10.1038/nrm2245.
23. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5:726-34; PMID:16148885; DOI:10.1038/nrc1692.
24. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005; 6:439-48; PMID:15928708; DOI:10.1038/nrm1660.
25. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007; 21:1367-81; PMID:17510285; DOI:10.1101/gad.1545107.
26. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7:961-7; PMID:17972889; DOI:10.1038/nrc2254.
27. Vazquez-Martin A, López-Bonetc E, Cufí S, Oliveras- Ferraros C, Del Barco S, Martin-Castillo B, et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 2011; 14:212-23; PMID:21600837.
28. Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Jovin TM. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005; 65:473-82; PMID:15695389.
29. Oliveras-Ferraros C, Vazquez-Martin A, Martin- Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol 2010; 37:669-78; PMID:20664936.
30. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585-92; PMID:15634652.
31. Oliveras-Ferraros C, Vazquez-Martin A, Martin- Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, et al. Dynamic emergence of the mesenchymal CD44(pos) CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 2010; 397:27-33; PMID:20470755; DOI:10.1016/j.bbrc.2010.05.041.
32. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126:355-64; PMID:20458531; DOI:10.1007/s10549-010-0924-x.
33. Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon- Christersson J, Osoegawa K, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007; 46:543-58; PMID:17334996; DOI:10.1002/gcc.20438.
34. -breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8:59; PMID:17062128; DOI:10.1186/bcr1610.
35. Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, Tanner M, et al. Oncolytic adeno-viruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther 2007; 15:2088-93; PMID:17848962; DOI:10.1038/sj.mt.6300300.
36. Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9:859-64; PMID:18704115; DOI:10.1038/embor.2008. 163.
37. Hanada T, Ohsumi Y. Structure-function relationship of Atg12, a ubiquitin-like modifier essential for autophagy. Autophagy 2005; 1:110-8; PMID:16874032; DOI:10.4161/auto.1.2.1858.
38. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004; 36:2503-18; PMID:15325588; DOI:10.1016/j.biocel.2004.05.009.
39. Tanida I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 2011; 14:2201-14; PMID:20712405; DOI:10.1089/ars.2010. 3482.
40. neg phenotype in breast cancer cell lines. Breast Cancer Res 2009; 11:82; PMID:19906290; DOI:10.1186/bcr2449.
41. Vesuna F, Lisok A, Kimble B, Raman V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009; 11:1318-28; PMID:20019840.
42. Bjørkøy G, Lamark T, Johansen T. p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2006; 2:138-9; PMID:16874037.
43. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; DOI:10.1074/jbc.M702824200.
44. Shvets E, Elazar Z. Autophagy-independent incorporation of GFP-LC3 into protein aggregates is dependent on its interaction with p62/SQSTM1. Autophagy 2008; 4:1054-6; PMID:18776740.
45. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 2007; 185:191-203; PMID:17587825; DOI:10.1159/000101320.
46. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30:1436-48; PMID:21057535; DOI:10.1038/onc.2010.509.
47. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGFbeta. Future Oncol 2009; 5:1145-68; PMID:19852727; DOI:10.2217/fon.09.90.
48. Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGFβ-induced EMT during cancer progression. Cell Tissue Res 2011; [Epub ahead of print].
49. Dang CV. Antimalarial therapy prevents Mycinduced lymphoma. J Clin Invest 2008; 118:15-7; PMID:18097478; DOI:10.1172/JCI34503.
50. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53Dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008; 118:79-88; PMID:18097482; DOI:10.1172/JCI33700.
51. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14:79-89; PMID:18598946; DOI:10.1016/j.ccr.2008.06.005.
52. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA 2011; [Epub ahead of print].
53. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011; 13:202; PMID:21392411.
54. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107:15449-54; PMID:20713713; DOI:10.1073/pnas.1004900107.
55. Turksen K. Claudins and Cancer Stem Cells. Stem Cell Rev 2011; [Epub ahead of print].
56. Ni HM, Bockus A, Wozniak AL, Jones K, Weinman S, Yin XM, et al. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. Autophagy 2011; 7:188-204; PMID:21107021; DOI:10.4161/auto.7.2.14181.
57. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8; PMID:12629218; DOI:10.1073/pnas.0530291100.
58. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100:672-9; PMID:18445819; DOI:10.1093/jnci/djn123.
59. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009; 14:55-66; PMID:19259796; DOI:10.1007/s10911-009-9116-x.
60. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist Updat 2010; 13:99-108; PMID:20739212; DOI:10.1016/j.drup.2010.08.001.
61. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28:4006-12; PMID:20498387; DOI:10.1200/JCO.2009.27.5388.
62. Raimondi C, Gianni W, Cortesi E, Gazzaniga P. Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug Targets 2010; 10:496-508; PMID:20384575; DOI:10.2174/ 156800910791517154.
63. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factorbeta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010; 15:169-90; PMID:20467795; DOI:10.1007/s10911-010-9181-1.
64. Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE, et al. Keratin downregulation in vimentin- positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther 2008; 7:2894-903; PMID:18790770; DOI:10.1158/1535-7163.MCT-08-0450.
65. Shvets E, Fass E, Scherz-Shouval R, Elazar Z. The N-terminus and Phe52 residue of LC3 recruit p62/ SQSTM1 into autophagosomes. J Cell Sci 2008; 121:2685-95; PMID:18653543; DOI:10.1242/jcs.026005.
66. Narita M, Young AR, Narita M. Autophagy facilitates oncogene-induced senescence. Autophagy 2009; 5:1046-7; PMID:19652542; DOI:10.4161/auto.5.7.9444.
67. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, et al. Autophagy mediates the mitotic senescence transition. Genes Dev 2009; 23:798-803; PMID:19279323; DOI:10.1101/gad.519709.
68. Serrano M. Cancer: a lower bar for senescence. Nature 2010; 464:363-4; PMID:20237557; DOI:10.1038/464363a.
69. Cheng Y, Li H, Ren X, Niu T, Hait WN, Yang J. Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS ONE 2010; 5:9715; PMID:20300520; DOI:10.1371/journal.pone.0009715.
70. Eimer S, Belaud-Rotureau MA, Airiau K, Jeanneteau M, Laharanne E, Véron N, et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther 2011; 11:1017-27; PMID:21508666; DOI:10.4161/cbt.11.12.15693.
71. Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, et al. EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells. PLoS ONE 2011; 6:18691; PMID:21655094; DOI:10.1371/journal.pone.0018691.
72. Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 2010; 70:5942-52; PMID:20634405; DOI:10.1158/0008-5472.CAN-10-0157.
73. Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 2010; 6:1066-77; PMID:20864811; DOI:10.4161/auto.6.8.13366.
74. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS ONE 2009; 4:6251; PMID:19606230; DOI:10.1371/journal. pone.0006251.
75. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13:58-68; PMID:18167340; DOI:10.1016/j.ccr.2007.12.003.
76. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007; 21:1621-35; PMID:17606641; DOI:10.1101/gad. 1565707.
77. Evdokimova V, Tognon C, Ng T, Sorensen PH. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009; 8:2901-6; PMID:19713745; DOI:10.4161/cc.8.18.9537.
78. Smit MA, Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging 2010; 2:735-41; PMID:20975209.
79. Zlobec I, Lugli A. Epithelial-mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1:651-61; PMID:21317460.
80. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFâ-induced epithelial-to- mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010; 9:4461-8; PMID:21088486; DOI:10.4161/cc.9.22.14048.
81. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGFâ and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010; 9:2363-74; PMID:20519943; DOI:10.4161/cc.9.12.12050.
82. Liu Y, Dean DC. Tumor initiation via loss of cell contact inhibition versus Ras mutation: do all roads lead to EMT? Cell Cycle 2010; 9:897-900; PMID:20160473; DOI:10.4161/cc.9.5.10933.
83. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009; 19:106-11; PMID:19249648; DOI:10.1016/j.semradonc.2008.12.002.
84. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174:1588-93; PMID:19342369; DOI:10.2353/ajpath.2009.080545.
85. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007; 101:816-29; PMID:17243120; DOI:10.1002/jcb.21215.
86. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003; 5:101-6; PMID:12631389; DOI:10.1186/bcr578.
87. Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 2011; 13:45; PMID:21501518; DOI:10.1186/bcr2867.
88. low population which is invasive and resistant to anoikis. Cancer Cell Int 2009; 9:11; PMID:19422694; DOI:10.1186/1475-2867-9-11.
89. Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. A Twist-Snail axis critical for TrkB-induced epithelialmesenchymal transition-like transformation, anoikis resistance and metastasis. Mol Cell Biol 2009; 29:3722-37; PMID:19414595; DOI:10.1128/MCB.01164-08.
90. Smit MA, Peeper DS. Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011; 30:3735-44; PMID:21478908; DOI:10.1038/onc.2011.96.
91. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009; 1796:75-90.
92. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19:797-806; PMID:18094039; DOI:10.1091/mbc.E07-10-1092.
93. Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol 2010; 22:241-5; PMID:19945838; DOI:10.1016/j.ceb.2009.10.008.
94. Lock R, Debnath J. Extracellular matrix regulation of autophagy. Curr Opin Cell Biol 2008; 20:583-8; PMID:18573652; DOI:10.1016/j.ceb.2008.05.002.
95. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, et al. Autophagy facilitates glycolysis during Rasmediated oncogenic transformation. Mol Biol Cell 2011; 22:165-78; PMID:21119005; DOI:10.1091/mbc.E10-06-0500.
96. Kiyono K, Suzuki HI, Matsuyama H, Morishita Y, Komuro A, Kano MR, et al. Autophagy is activated by TGFbeta and potentiates TGFbeta-mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res 2009; 69:8844-52; PMID:19903843; DOI:10.1158/0008-5472.CAN-08-4401.
97. Suzuki HI, Kiyono K, Miyazono K. Regulation of autophagy by transforming growth factor-beta (TGFbeta) signaling. Autophagy 2010; 6; [Epub ahead of print]; PMID:20458184; DOI:10.4161/auto.6.5.12046.
98. Caja L, Bertran E, Campbell J, Fausto N, Fabregat I. The transforming growth factor-beta (TGFβ) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol 2011; 226:1214-23; PMID:20945437; DOI:10.1002/jcp.22439.
99. Tu YF, Kaipparettu BA, Ma Y, Wong LJ. Mitochondria of highly metastatic breast cancer cell line MDA-MB-231 exhibits increased autophagic properties. Biochim Biophys Acta 2011; 1807:1125-32.
100. Avivar-Valderas A, Salas E, Bobrovnikova-Marjon E, Diehl JA, Nagi C, Debnath J, et al. PERK integrates autophagy and oxidative stress responses to promote survival during ECM detachment. Mol Cell Biol 2011; 31:3616-29; PMID:21709020; DOI:10.1128/MCB.05164-11.
101. Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, et al. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem 2011; 286:12924-32; PMID:21300795; DOI:10.1074/jbc.M110.138958.
102. Kim JH, Kim HY, Lee YK, Yoon YS, Xu WG, Yoon JK, et al. Involvement of mitophagy in oncogenic K-Rasinduced transformation: Overcoming a cellular energy deficit from glucose deficiency. Autophagy 2011; 7; [Epub ahead of print]; PMID:21738012.
103. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011; 10:908-11; PMID:21615676; DOI:10.1111/j.1474-9726.2011.00722.x.
104. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2:24.
105. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584:1287-95; PMID:20083114; DOI:10.1016/j.febslet.2010.01.017.
106. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116:4560-8; PMID:20686120; DOI:10.1182/blood-2010-05-285726.
107. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008; 100:133-58; PMID:18620095; DOI:10.1016/S0065-230X(08)00005- 5.
108. Menendez S, Camus S, Izpisua Belmonte JC. p53: guardian of reprogramming. Cell Cycle 2010; 9:3887-91; PMID:20948296; DOI:10.4161/cc.9.19.13301.
109. Narita M. Quality control of proteins in senescence. Aging 2010; 2:311-4; PMID:20519777.
110. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging 2009; 1:586-97; PMID:20157541.
111. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010; 1:497-514; PMID:21165163.
112. Huang Y, Ratovitski EA. Phospho-ΔNp63α/Rpn13Dependent regulation of LKB1 degradation modulates autophagy in cancer cells. Aging 2010; 2:959-68; PMID:21191146.